Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
INFI's Cash to Debt is ranked higher than
94% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. INFI: No Debt )
INFI' s 10-Year Cash to Debt Range
Min: 0.28   Max: 13254
Current: No Debt

0.28
13254
F-Score: 3
Z-Score: 5.18
M-Score: -3.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -62.99
INFI's ROE (%) is ranked higher than
59% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. INFI: -62.99 )
INFI' s 10-Year ROE (%) Range
Min: -357.47   Max: 19.66
Current: -62.99

-357.47
19.66
ROA (%) -54.95
INFI's ROA (%) is ranked higher than
58% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. INFI: -54.95 )
INFI' s 10-Year ROA (%) Range
Min: -148.74   Max: 14.73
Current: -54.95

-148.74
14.73
ROC (Joel Greenblatt) (%) -3183.94
INFI's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. INFI: -3183.94 )
INFI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3183.94   Max: 359.74
Current: -3183.94

-3183.94
359.74
Revenue Growth (%) -100.00
INFI's Revenue Growth (%) is ranked higher than
51% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. INFI: -100.00 )
INFI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 155.9
Current: -100

0
155.9
EBITDA Growth (%) 14.70
INFI's EBITDA Growth (%) is ranked higher than
89% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. INFI: 14.70 )
INFI' s 10-Year EBITDA Growth (%) Range
Min: -64.6   Max: 261.4
Current: 14.7

-64.6
261.4
EPS Growth (%) 12.40
INFI's EPS Growth (%) is ranked higher than
88% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. INFI: 12.40 )
INFI' s 10-Year EPS Growth (%) Range
Min: -64   Max: 115.9
Current: 12.4

-64
115.9
» INFI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

INFI Guru Trades in Q3 2013

Steven Cohen 4,094,600 sh (+121.58%)
Paul Tudor Jones Sold Out
Jim Simons 207,600 sh (-19.13%)
» More
Q4 2013

INFI Guru Trades in Q4 2013

Jim Simons 763,600 sh (+267.82%)
Steven Cohen 3,555,500 sh (-13.17%)
» More
Q1 2014

INFI Guru Trades in Q1 2014

John Burbank 16,556 sh (New)
Steven Cohen 3,411,659 sh (-4.05%)
Jim Simons 498,540 sh (-34.71%)
» More
Q2 2014

INFI Guru Trades in Q2 2014

Chuck Royce 123,400 sh (New)
Steven Cohen 3,410,978 sh (unchged)
John Burbank Sold Out
Jim Simons 198,600 sh (-60.16%)
» More
» Details

Insider Trades

Latest Guru Trades with INFI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-06-30 Sold Out 0.01%$8.6 - $12.67 $ 10.945%0
John Burbank 2014-03-31 New Buy0.01%$11.37 - $16.52 $ 10.94-19%16556
George Soros 2013-06-30 Sold Out 0.02%$16.192 - $50.09 $ 10.94-65%0
George Soros 2013-03-31 Reduce -46.67%0.01%$32.93 - $49.37 $ 10.94-72%40000
George Soros 2012-12-31 New Buy0.03%$17.74 - $35.04 $ 10.94-57%75000
Jean-Marie Eveillard 2012-06-30 Sold Out 0.01%$11.71 - $13.76 $ 10.94-14%0
Jean-Marie Eveillard 2012-03-31 Reduce -54.94%0.01%$5.9781 - $12.16 $ 10.9437%180000
Jean-Marie Eveillard 2011-09-30 Reduce -25.85%0.01%$6.17 - $10.36 $ 10.9439%464241
Wilbur Ross 2011-06-30 Sold Out $5.61 - $8.19 $ 10.9468%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.80
INFI's P/B is ranked higher than
72% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. INFI: 3.80 )
INFI' s 10-Year P/B Range
Min: 0.6   Max: 51.23
Current: 3.8

0.6
51.23
EV-to-EBIT -2.48
INFI's EV-to-EBIT is ranked lower than
51% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INFI: -2.48 )
INFI' s 10-Year EV-to-EBIT Range
Min: 0.3   Max: 493.6
Current: -2.48

0.3
493.6
Current Ratio 6.04
INFI's Current Ratio is ranked higher than
81% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. INFI: 6.04 )
INFI' s 10-Year Current Ratio Range
Min: 0.64   Max: 17.81
Current: 6.04

0.64
17.81
Quick Ratio 6.04
INFI's Quick Ratio is ranked higher than
81% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. INFI: 6.04 )
INFI' s 10-Year Quick Ratio Range
Min: 0.41   Max: 17.81
Current: 6.04

0.41
17.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.70
INFI's Price/Net Cash is ranked higher than
88% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INFI: 4.70 )
INFI' s 10-Year Price/Net Cash Range
Min: 0.87   Max: 38.43
Current: 4.7

0.87
38.43
Price/Net Current Asset Value 4.70
INFI's Price/Net Current Asset Value is ranked higher than
86% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. INFI: 4.70 )
INFI' s 10-Year Price/Net Current Asset Value Range
Min: 0.85   Max: 36.83
Current: 4.7

0.85
36.83
Price/Tangible Book 3.80
INFI's Price/Tangible Book is ranked higher than
77% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. INFI: 3.80 )
INFI' s 10-Year Price/Tangible Book Range
Min: 0.74   Max: 46
Current: 3.8

0.74
46
Price/Median PS Value 1.00
INFI's Price/Median PS Value is ranked higher than
67% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. INFI: 1.00 )
INFI' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 18.64
Current: 1

0.36
18.64
Earnings Yield (Greenblatt) 74.10
INFI's Earnings Yield (Greenblatt) is ranked higher than
86% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. INFI: 74.10 )
INFI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 289.4
Current: 74.1

0.2
289.4
Forward Rate of Return (Yacktman) -8.62
INFI's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. INFI: -8.62 )
INFI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -72.4   Max: -42.5
Current: -8.62

-72.4
-42.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:I3F.Germany
Infinity Pharmaceuticals, Inc was incorporated in California on March 22, 1995 under the name IRORI and, in 1998, the Company changed its name to Discovery Partners International, Inc., or DPI. On September 12, 2006, DPI completed a merger with Infinity Pharmaceuticals, Inc., or IPI, to which a wholly-owned subsidiary of DPI merged with and into IPI. IPI was the surviving corporation in the merger, changed its name to Infinity Discovery, Inc., or IDI, and became a wholly owned subsidiary of DPI. The Company changed its corporate name from Discovery Partners International, Inc. to Infinity Pharmaceuticals, Inc. The Company discovers, develops, and delivers medicines for the treatment of cancer and related conditions. The Company's product candidate is saridegib, a novel, potent, oral molecule that inhibits the Hedgehog pathway by binding to the Smoothened receptor, a protein that plays a critical role in the malignant activation of the Hedgehog pathway. The Company is evaluating saridegib in a randomized, double-blind Phase 2 clinical trial to assess the safety and efficacy of saridegib compared to placebo in approximately 140 patients with metastatic or locally advanced, inoperable chondrosarcoma. The Company is also enrolling patients in an exploratory Phase 2 clinical trial evaluating the safety and efficacy of saridegib in patients with myelofibrosis. Retaspimycin hydrochloride (HCl), , is a novel, potent and selective inhibitor of heat shock protein 90, or Hsp90. Cancer cells depend on Hsp90 to maintain many proteins critical for cancer growth, proliferation and survival in a functional state. Retaspimycin HCl is currently being evaluated in a randomized, double-blind Phase 2 clinical trial in combination with docetaxel, a chemotherapy, compared to placebo and docetaxel in approximately 200 patients with second- or third-line non-small cell lung cancer, or NSCLC, who are naive to docetaxel treatment and have a history of heavy smoking. The Company is also enrolling patients in a Phase 1b/2 trial to explore the safety and efficacy of retaspimycin HCl in combination with everolimus, an mTOR inhibitor, in NSCLC patients with a KRAS mutation. The Company's compound in this PI3K Inhibitor Program is IPI-145, a potent, orally-available inhibitor of PI3K-delta and PI3K-gamma. PI3Ks, are a family of enzymes involved in key immune cell functions, including cell proliferation and survival, cell differentiation, and cellular trafficking. PI3K-delta and PI3K-gamma, two isoforms of PI3K, play key roles in inflammatory and autoimmune diseases. Government authorities in the United States and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, storage, recordkeeping, approval, promotion, labeling, advertising, distribution, marketing, post-approval monitoring and reporting, sampling, and export and import of pharmaceutical products such as those it is developing.
» More Articles for INFI

Headlines

Articles On GuruFocus.com
comment on INFI Mar 02 2013 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 04 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) May 06 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 06 2009 
Infinity Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
INFINITY PHARMACEUTICALS, INC. Financials Aug 19 2014
INFINITY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014
Traders see no going back for Infinity Aug 06 2014
Infinity Reports Second Quarter 2014 Financial Results and Provides Company Update Aug 05 2014
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 05 2014
Infinity Reports Second Quarter 2014 Financial Results and Provides Company Update Aug 05 2014
Q2 2014 Infinity Pharmaceuticals, Inc. Earnings Release - Before Market Open Aug 05 2014
Infinity Amends PI3K-Delta, Gamma Agreement with Millennium Aug 04 2014
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Aug 04 2014
Infinity Amends PI3K-Delta, Gamma Agreement with Millennium Aug 04 2014
Infinity Announces the Date of Its Second Quarter 2014 Financial Results Conference Call and Webcast Jul 24 2014
Infinity Announces the Date of Its Second Quarter 2014 Financial Results Conference Call and Webcast Jul 24 2014
Infinity to Participate in the BMO Capital Markets 3RD Annual Biotech Corporate Access Day Jul 22 2014
Infinity to Participate in the BMO Capital Markets 3RD Annual Biotech Corporate Access Day Jul 22 2014
3 Small-Cap Biotechs That Institutions Are Loving Jul 07 2014
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 19 2014
Five Biotech Stocks With Big Potential And Billionaire Believers Jun 16 2014
Infinity to Present at the Goldman Sachs 35th Annual Global Healthcare Conference Jun 03 2014
Infinity to Participate in Four Conferences in June May 27 2014
Gilead study 'alarming,' says Stifel May 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide